Cardiovascular Systems/ US1416191062 /
2023-04-27 10:00:00 PM | Chg. - | Volume | Bid10:01:29 PM | Ask11:02:00 PM | High | Low |
---|---|---|---|---|---|---|
20.0000USD | - | 398,334 Turnover: 6.86 mill. |
19.9900Bid Size: 100 | 20.0000Ask Size: 2,300 | 20.0000 | 19.9800 |
GlobeNewswire
7:00 AM
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-09
Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Prog...
GlobeNewswire
05-09
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GlobeNewswire
05-08
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-08
Will your health insurance cover weight-loss medications? It depends on several factors, including w...
GlobeNewswire
05-08
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population ...
GlobeNewswire
05-08
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...
GlobeNewswire
05-08
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-07
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating V...
GlobeNewswire
05-03
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
05-02
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results ...
GlobeNewswire
04-30
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertens...
GlobeNewswire
04-29
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-...
GlobeNewswire
04-29
Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 ...
GlobeNewswire
04-29
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 ...